Coronavirus vaccination - Revision history

Tania.Dexter@anthonynolan.org at 14:18, 22 October 2024

2024-10-22T14:18:53Z

Ruta.Maniusyte@anthonynolan.org at 08:44, 27 September 2021

2021-09-27T08:44:14Z

Ruta.Maniusyte@anthonynolan.org at 08:43, 27 September 2021

2021-09-27T08:43:08Z

Angharad.Pryce@anthonynolan.org at 10:06, 5 May 2021

2021-05-05T10:06:46Z

Angharad.Pryce@anthonynolan.org at 10:04, 5 May 2021

2021-05-05T10:04:46Z

Angharad.Pryce@anthonynolan.org at 10:03, 5 May 2021

2021-05-05T10:03:33Z

Angharad.Pryce@anthonynolan.org at 11:36, 5 January 2021

2021-01-05T11:36:11Z

Angharad.Pryce@anthonynolan.org at 11:35, 5 January 2021

2021-01-05T11:35:35Z

Angharad.Pryce@anthonynolan.org at 11:27, 5 January 2021

2021-01-05T11:27:17Z

Angharad.Pryce@anthonynolan.org at 11:26, 5 January 2021

2021-01-05T11:26:49Z

@@ Line 40: / Line 40: @@
 '''Discretionary'''
-If the transplant cannot be delayed, Donors may be accepted less than 14
+Donors may be accepted less than 14 days (nucleic acid vaccines) or 28 days (viral vector vaccines) after the date of the most recent vaccination, if vaccinated as part of the UK vaccination
-days (nucleic acid vaccines) or 28 days (viral vector vaccines) after the date
+programme, subject to individual risk assessment and in discussion with the TC.
-of the most recent vaccination, if vaccinated as part of the UK vaccination
+The TC should be informed regarding any covid vaccination within 3 months as per "immunisation" guideline.
-programme, subject to individual risk assessment, discuss with Medical Officer. More flexibility exists with 2nd dose of vaccination. See additional information.
 '''Boosters'''

@@ Line 1: / Line 1: @@
 '''Acceptability at Recruitment'''
 Qualified
 '''Acceptability at CT/Workup'''
 Qualified
@@ Line 44: / Line 46: @@
 '''Boosters'''
 Same rules as per 2nd dose of vaccination.

@@ Line 41: / Line 41: @@
 days (nucleic acid vaccines) or 28 days (viral vector vaccines) after the date
 of the most recent vaccination, if vaccinated as part of the UK vaccination
-programme, subject to individual risk assessment, discuss with Medical Officer. See additional information.
+programme, subject to individual risk assessment, discuss with Medical Officer. More flexibility exists with 2nd dose of vaccination. See additional information.
 '''
-See if relevant'''
+'''See if relevant'''
 [[Coronavirus]]

← Older revision		Revision as of 10:06, 5 May 2021
Line 51:		Line 51:

	All COVID-19 vaccines currently licensed in the UK are non-live. Normally, no deferral period is applied after immunisation with non-live vaccines. However as the effects of the newly developed coronavirus vaccines on donor health and donation safety are not fully established yet, as a precautionary principle, a 14 to 28 day post vaccine deferral period, depending on the type of vaccine is recommended.		All COVID-19 vaccines currently licensed in the UK are non-live. Normally, no deferral period is applied after immunisation with non-live vaccines. However as the effects of the newly developed coronavirus vaccines on donor health and donation safety are not fully established yet, as a precautionary principle, a 14 to 28 day post vaccine deferral period, depending on the type of vaccine is recommended.
		+
		+	mRNA vaccines include Pfizer and Moderna. Virus-Vector based vaccines include AstraZeneca and Johnson and Johnson.

	Immune thrombocytopenia (ITP) can occur after all types of Covid 19 vaccines. There have been a small number of reports of vaccine induced thrombosis and thrombocytopenia syndrome (VITTS), in people receiving virus vector based (non-replicating) coronavirus vaccine. VITTS patients have severe clinical symptoms whilst ITP may be sub-clinical and go unnoticed on symptoms alone. The incidence is unclear but may be similar to other vaccine induced ITP.		Immune thrombocytopenia (ITP) can occur after all types of Covid 19 vaccines. There have been a small number of reports of vaccine induced thrombosis and thrombocytopenia syndrome (VITTS), in people receiving virus vector based (non-replicating) coronavirus vaccine. VITTS patients have severe clinical symptoms whilst ITP may be sub-clinical and go unnoticed on symptoms alone. The incidence is unclear but may be similar to other vaccine induced ITP.

@@ Line 9: / Line 9: @@
 '''Obligatory'''
-a)Recipients of a COVID-19 vaccine in the UK vaccination programme
+a) Recipients of a COVID-19 vaccine in the UK vaccination programme
 Must not donate if:
 i) Less than 14 days after the last immunization if the
 vaccine given was nucleic acid (mRNA) vaccine.
 ii) Less than 28 days after the last immunization if the vaccine given was
 virus-vector-based (non-replicating virus) vaccine
 See additional information for further information on different types of vaccine.
 iii) If donor felt unwell due to unexpected complications (other than common
 side effects) after any vaccination refer to Medical Officer for individual risk
 assessment.
 Timings above refer to interval between vaccination and start of G-CSF or
 general anaesthetic for BM donation.
 b) Recipients of a COVID-19 vaccine outside the UK vaccination

@@ Line 9: / Line 9: @@
 '''Obligatory'''
-a) UK vaccination programme (Recipients of the Pfizer/BioNTech Covid-19 vaccine or the AstraZeneca COVID-19 vaccine)
+a)Recipients of a COVID-19 vaccine in the UK vaccination programme
-Must not donate if;
+b) Recipients of a COVID-19 vaccine outside the UK vaccination
-i) Less than seven days after the most recent vaccination was given (to start of G-CSF)
+Refer to Medical Officer for individual risk assessment.
-b) Recipients of any other Covid-19 vaccine, including participants in clinical trials or donors vaccinated outside the UK.
+'''Discretionary'''
-'''Discretionary'''
+If the transplant cannot be delayed, Donors may be accepted less than 14
 '''
@@ Line 33: / Line 45: @@
 '''Additional Information'''
-Individuals vaccinated with inactivated viruses of vaccines that do not contain live agents (ie. mRNA and protein subunit vaccines) may be accepted as tissue and cell donors if they feel well after vaccination. After vaccination with attenuated viruses (e.g. virus vector based other than non-replicated or live-attenuated virus vaccines) tissue and cell donors must be deferred for four weeks.
+All COVID-19 vaccines currently licensed in the UK are non-live. Normally, no deferral period is applied after immunisation with non-live vaccines. However as the effects of the newly developed coronavirus vaccines on donor health and donation safety are not fully established yet, as a precautionary principle, a 14 to 28 day post vaccine deferral period, depending on the type of vaccine is recommended.
 For donors vaccinated as part of a clinical trial or outside of the UK, the type of vaccine used should be established to determine the appropriate deferral period.
@@ Line 42: / Line 55: @@
 There may be new types of vaccine that become available, and it may not be known which type of vaccine was used for immunization. In situation where information about vaccine type is missing or the vaccination is experimental, a four week deferral period should be applied.
-The ECDC recommends that if HSC donors have been vaccinated with attenuated vaccines int eh four weeks before donation, a risk assessment should be carried out and taken into account when deciding on transplantation, and if transplanted, the recipient should be monitored post-transplant.

@@ Line 29: / Line 29: @@
 '''
 See if relevant'''
-Coronavirus Infection
+[[Coronavirus Infection]]
 '''Additional Information'''

@@ Line 47: / Line 47: @@
 {| class="wikitable"
 |-
-! Disease Protected against !!  Comments and examples of trade names/preparations   !! Header text
+! Disease Protected against !!  Comments and examples of trade names/preparations   !!
 |-
 | COVID019 (SARS-CoV-2) || Pfizer/BioNTech COVID-19 vaccine. AstraZeneca Covid-19 vaccine. || Non-live
 |}

← Older revision		Revision as of 11:26, 5 January 2021
Line 43:		Line 43:

	The ECDC recommends that if HSC donors have been vaccinated with attenuated vaccines int eh four weeks before donation, a risk assessment should be carried out and taken into account when deciding on transplantation, and if transplanted, the recipient should be monitored post-transplant.		The ECDC recommends that if HSC donors have been vaccinated with attenuated vaccines int eh four weeks before donation, a risk assessment should be carried out and taken into account when deciding on transplantation, and if transplanted, the recipient should be monitored post-transplant.
		+
		+
		+	{\| class="wikitable"
		+	\|-
		+	! Disease Protected against !! Comments and examples of trade names/preparations !! Header text
		+	\|-
		+	\| COVID019 (SARS-CoV-2) \|\| Pfizer/BioNTech COVID-19 vaccine. AstraZeneca Covid-19 vaccine. \|\| Non-live
		+	\|-
		+	\| Example \|\| Example \|\| Example
		+	\|}